Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVN461 for Post-Operative Ocular Inflammation
NCT06164743Phase 2Completed
- Sponsor
- VivaVision Biotech
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VVN461 in ocular inflammation, sponsored by VivaVision Biotech. Started Jan 2024; status: completed.
02
Drugs
VVN461
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT06164743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164743.